ANN ARBOR, Mich., Jan. 15, 2008 (PRIME NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that the first patient has been treated with the Company's autologous stem cell therapy for dilated cardiomyopathy (DCM). The milestone marks the first human application of Aastrom's Cardiac Repair Cell (CRC) product to regenerate damaged heart tissue in patients with severely impaired cardiac function.
